Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role
Tóm tắt
Ovarian cancer affects more than 200,000 women each year around the world. Most women are not diagnosed until the disease has already metastasized from the ovaries with a resultant poor prognosis. Ovarian cancer is associated with an overall 5 year survival of little more than 50%. The mainstay of front-line therapy is cytoreductive surgery followed by chemotherapy. Traditionally, this has been by the intravenous route only but there is more interest in the delivery of intraperitoneal chemotherapy utilizing the pharmaco-therapeutic advantage of the peritoneal barrier. Despite three large, randomized clinical trials comparing intravenous with intraperitoneal chemotherapy showing improved outcomes for those receiving at least part of their chemotherapy by the intraperitoneal route. Cisplatin has been the most active drug for the treatment of ovarian cancer for the last 4 decades and the prognosis for women with ovarian cancer can be defined by the tumor response to cisplatin. Those whose tumors are innately platinum-resistant at the time of initial treatment have a very poor prognosis. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy the majority will develop disease that becomes resistant to cisplatin and will ultimately succumb to the disease. Improving the efficacy of cisplatin could have a major impact in the fight against this disease. Arsenite is an exciting agent that not only has inherent single-agent tumoricidal activity against ovarian cancer cell lines but also multiple biochemical interactions that may enhance the cytotoxicity of cisplatin including inhibition of deoxyribose nucleic acid (DNA) repair. In vitro studies suggest that arsenite may enhance the activity of cisplatin in other cell types. Arsenic trioxide is already used clinically to treat acute promyelocytic leukemia demonstrating its safety profile. Further research in ovarian cancer is warranted to define its possible role in this disease.
Tài liệu tham khảo
citation_journal_title=CA Cancer J Clin; citation_title=Global Cancer Statistics; citation_author=DM Parkin, F Bray, J Ferlay; citation_volume=55; citation_publication_date=2005; citation_pages=74-108; citation_doi=10.3322/canjclin.55.2.74; citation_id=CR1
citation_inbook_title=Cancer Facts and Figures; citation_publication_date=2008; citation_id=CR2; citation_author=AC Society
citation_journal_title=Semin Oncol; citation_title=Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group); citation_author=WP McGuire, WJ Hoskins, MF Brady; citation_volume=23; citation_publication_date=1996; citation_pages=40-47; citation_id=CR3
citation_inbook_title=Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study[see comment]; citation_publication_date=2000; citation_pages=106-115; citation_id=CR4; citation_author=FM Muggia; citation_author=PS Braly; citation_author=MF Brady
citation_journal_title=J Clin Oncol; citation_title=Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study[see comment]; citation_author=RF Ozols, BN Bundy, BE Greer; citation_volume=21; citation_publication_date=2003; citation_pages=3194-3200; citation_doi=10.1200/JCO.2003.02.153; citation_id=CR5
citation_journal_title=J Clin Oncol; citation_title=Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer[see comment]. [erratum appears in J Clin Oncol 1992 Sep, 10(9):1505]; citation_author=DS Alberts, S Green, EV Hannigan; citation_volume=10; citation_publication_date=1992; citation_pages=706-717; citation_id=CR6
citation_journal_title=Am J Obstet Gynecol; citation_title=The changing prognosis and treatment in cancer of the ovary; citation_author=E Munnell; citation_volume=100; citation_publication_date=1968; citation_pages=790-795; citation_id=CR7
citation_journal_title=Nat Cancer Inst Monog; citation_title=Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma; citation_author=CT Griffiths; citation_volume=42; citation_publication_date=1975; citation_pages=101-104; citation_id=CR8
citation_journal_title=Gynecol Oncol; citation_title=Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study; citation_author=SM Eisenkop, RL Friedman, HJ Wang; citation_volume=69; citation_publication_date=1998; citation_pages=103-108; citation_doi=10.1006/gyno.1998.4955; citation_id=CR9
citation_journal_title=Gynecol Oncol; citation_title=The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study; citation_author=WJ Hoskins, BN Bundy, JT Thigpen; citation_volume=47; citation_publication_date=1992; citation_pages=159-166; citation_doi=10.1016/0090-8258(92)90100-W; citation_id=CR10
citation_journal_title=Gynecol Oncol; citation_title=Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer; citation_author=F Guidozzi, JH Ball; citation_volume=53; citation_publication_date=1994; citation_pages=326-330; citation_doi=10.1006/gyno.1994.1142; citation_id=CR11
citation_journal_title=J Clin Oncol; citation_title=Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis; citation_author=RE Bristow, RS Tomacruz, DK Armstrong; citation_volume=20; citation_publication_date=2002; citation_pages=1248-1259; citation_doi=10.1200/JCO.20.5.1248; citation_id=CR12
citation_journal_title=Am J Obstet Gynecol; citation_title=The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma; citation_author=WJ Hoskins, WP McGuire, MF Brady; citation_volume=170; citation_publication_date=1994; citation_pages=974-979; citation_doi=10.1016/S0002-9378(94)70090-7; citation_id=CR13
citation_journal_title=Gynecol Oncol; citation_title=What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?; citation_author=SM Eisenkop, NM Spirtos; citation_volume=82; citation_publication_date=2001; citation_pages=489-497; citation_doi=10.1006/gyno.2001.6312; citation_id=CR14
citation_journal_title=Obstet Gynecol; citation_title=Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings; citation_author=SC Rubin, TC Randall, KA Armstrong; citation_volume=93; citation_publication_date=1999; citation_pages=21-24; citation_doi=10.1016/S0029-7844(98)00334-2; citation_id=CR15
citation_journal_title=Nature; citation_title=Platinum compounds: a new class of potent antitumour agents; citation_author=B Rosenberg, L VanCamp, JE Trosko; citation_volume=222; citation_publication_date=1969; citation_pages=385-386; citation_doi=10.1038/222385a0; citation_id=CR16
citation_inbook_title=Cisplatin and Its Analogues; citation_publication_date=2001; citation_pages=376-388; citation_id=CR17; citation_author=SW Johnson; citation_author=JP Stevenson; citation_author=PJ O'Dwyer; citation_author=VT DeVita; citation_author=S Hellman; citation_author=SA Rosenberg; citation_publisher=Lippincott Williams and Wilkins
citation_journal_title=Cancer; citation_title=Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model; citation_author=E Cvitkovic, J Spaulding, V Bethune; citation_volume=39; citation_publication_date=1977; citation_pages=1357-1361; citation_doi=10.1002/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C; citation_id=CR18
citation_journal_title=Cancer; citation_title=High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis; citation_author=DM Hayes, E Cvitkovic, RB Golbey; citation_volume=39; citation_publication_date=1977; citation_pages=1372-1381; citation_doi=10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J; citation_id=CR19
citation_journal_title=Br Med J (Clin Res Ed); citation_title=High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group; citation_author=HE Lambert, RJ Berry; citation_volume=290; citation_publication_date=1985; citation_pages=889-893; citation_doi=10.1136/bmj.290.6472.889; citation_id=CR20
citation_inbook_title=Epithelial Ovarian Cancer; citation_publication_date=2000; citation_pages=981-1057; citation_id=CR21; citation_author=RF Ozols; citation_author=SC Rubin; citation_author=GM Thomas; citation_author=WJ Hoskins; citation_author=CA Perez; citation_author=RC Young; citation_publisher=Lippincott Williams and Wilkins
citation_journal_title=Obstet Gynecol; citation_title=Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma; citation_author=DG Decker, TR Fleming, GD Malkasian; citation_volume=60; citation_publication_date=1982; citation_pages=481-487; citation_id=CR22
citation_journal_title=Cancer; citation_title=A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study; citation_author=G Omura, JA Blessing, CE Ehrlich; citation_volume=57; citation_publication_date=1986; citation_pages=1725-1730; citation_doi=10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; citation_id=CR23
citation_journal_title=Lancet; citation_title=Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma; citation_author=JP Neijt, WW ten Bokkel Huinink, MEvan der Burg; citation_volume=2; citation_publication_date=1984; citation_pages=594-600; citation_doi=10.1016/S0140-6736(84)90594-4; citation_id=CR24
citation_inbook_title=Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials; citation_publication_date=1991; citation_pages=884-893; citation_id=CR25
citation_journal_title=J Natl Cancer Inst; citation_title=Taxol: a novel investigational antimicrotubule agent; citation_author=EK Rowinsky, LA Cazenave, RC Donehower; citation_volume=82; citation_publication_date=1990; citation_pages=1247-1259; citation_doi=10.1093/jnci/82.15.1247; citation_id=CR26
citation_inbook_title=Paclitaxel (taxol); citation_publication_date=1995; citation_pages=1001-1014; citation_id=CR27; citation_author=EK Rowinsky; citation_author=RC Donehower
citation_inbook_title=Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms; citation_publication_date=1989; citation_pages=273-279; citation_id=CR28; citation_author=WP McGuire; citation_author=EK Rowinsky; citation_author=NB Rosenshein
citation_journal_title=Nature; citation_title=Promotion of microtubule assembly in vitro by taxol; citation_author=PB Schiff, J Fant, SB Horwitz; citation_volume=277; citation_publication_date=1979; citation_pages=665-667; citation_doi=10.1038/277665a0; citation_id=CR29
citation_journal_title=Proc Natl Acad Sci USA; citation_title=Taxol stabilizes microtubules in mouse fibroblast cells; citation_author=PB Schiff, SB Horwitz; citation_volume=77; citation_publication_date=1980; citation_pages=1561-1565; citation_doi=10.1073/pnas.77.3.1561; citation_id=CR30
citation_journal_title=J Cell Biol; citation_title=Taxol binds to cellular microtubules; citation_author=JJ Manfredi, J Parness, SB Horwitz; citation_volume=94; citation_publication_date=1982; citation_pages=688-696; citation_doi=10.1083/jcb.94.3.688; citation_id=CR31
citation_journal_title=J Natl Cancer Inst; citation_title=Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol; citation_author=I Ringel, SB Horwitz; citation_volume=83; citation_publication_date=1991; citation_pages=288-291; citation_doi=10.1093/jnci/83.4.288; citation_id=CR32
citation_inbook_title=Early studies with cisdiamine 1, 1, cyclobutane dicarboxylate platinum II; citation_publication_date=1982; citation_pages=140; citation_id=CR33; citation_author=AH Calvert; citation_author=SJ Harland
citation_journal_title=Cancer Res; citation_title=A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240); citation_author=GA Curt, JJ Grygiel, BJ Corden; citation_volume=43; citation_publication_date=1983; citation_pages=4470-4473; citation_id=CR34
citation_journal_title=Cancer Treat Rep; citation_title=Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma; citation_author=BD Evans, KS Raju, AH Calvert; citation_volume=67; citation_publication_date=1983; citation_pages=997-1000; citation_id=CR35
citation_journal_title=Cancer Treat Rev; citation_title=Preclinical studies identifying carboplatin as a viable cisplatin alternative; citation_author=KR Harrap; citation_volume=12; citation_issue=Suppl A; citation_publication_date=1985; citation_pages=21-33; citation_doi=10.1016/0305-7372(85)90015-5; citation_id=CR36
citation_inbook_title=Carboplatin: current status and future prospects; citation_publication_date=1988; citation_pages=17; citation_id=CR37; citation_author=R Canetta; citation_author=K Bragman; citation_author=L Smaldone
citation_journal_title=Br J Cancer; citation_title=Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group; citation_author=K Aabo, M Adams, P Adnitt; citation_volume=78; citation_publication_date=1998; citation_pages=1479-1487; citation_doi=10.1038/bjc.1998.710; citation_id=CR38
citation_inbook_title=Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma; citation_publication_date=2004; citation_pages=1682-1691; citation_id=CR39; citation_author=PA Vasey; citation_author=GC Jayson; citation_author=A Gordon
citation_journal_title=Canc Treat Rep; citation_title=Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer; citation_author=RI Dedrick, CE Myers, PM Bungay; citation_volume=62; citation_publication_date=1978; citation_pages=1-11; citation_id=CR40
citation_journal_title=Exp Rev Anticanc Ther; citation_title=Intraperitoneal chemotherapy in the management of malignant disease; citation_author=M Markman; citation_volume=1; citation_publication_date=2001; citation_pages=142-148; citation_doi=10.1586/14737140.1.1.142; citation_id=CR41
citation_journal_title=N Engl J Med; citation_title=Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer[see comment]; citation_author=DS Alberts, PY Liu, EV Hannigan; citation_volume=335; citation_publication_date=1996; citation_pages=1950-1955; citation_doi=10.1056/NEJM199612263352603; citation_id=CR42
citation_journal_title=J Clin Oncol; citation_title=Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[see comment]; citation_author=M Markman, BN Bundy, DS Alberts; citation_volume=19; citation_publication_date=2001; citation_pages=1001-1007; citation_id=CR43
citation_journal_title=N Engl J Med; citation_title=Intraperitoneal cisplatin and paclitaxel in ovarian cancer; citation_author=DK Armstrong, BN Bundy, L Wenzel; citation_volume=354; citation_publication_date=2006; citation_pages=34-43; citation_doi=10.1056/NEJMoa052985; citation_id=CR44
citation_journal_title=Cochrane Database Systemat Rev; citation_title=Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer; citation_author=K Jaaback, N Johnson; citation_volume=25; citation_issue=1; citation_publication_date=2006; citation_pages=CD005340; citation_id=CR45
NCI Clinical Announcement For Preferred Method of Treatment for Advanced Ovarian Cancer
2006. [
http://ctep.cancer.gov/resources/gcig/icaoa.html
]
citation_journal_title=Pharmacol Ther; citation_title=The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes; citation_author=A Eastman; citation_volume=34; citation_publication_date=1987; citation_pages=155-166; citation_doi=10.1016/0163-7258(87)90009-X; citation_id=CR47
citation_journal_title=Br J Cancer; citation_title=Cellular accumulation of the anticancer agent cisplatin: a review; citation_author=DP Gately, SB Howell; citation_volume=67; citation_publication_date=1993; citation_pages=1171-1176; citation_doi=10.1038/bjc.1993.221; citation_id=CR48
citation_journal_title=Canc Res; citation_title=Potential for therapy of drugs and hyperthermia; citation_author=GM Hahn; citation_volume=39; citation_publication_date=1979; citation_pages=2264-2268; citation_id=CR49
citation_journal_title=Cancer Res; citation_title=Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II); citation_author=RE Meyn, PM Corry, SE Fletcher; citation_volume=40; citation_publication_date=1980; citation_pages=1136-1139; citation_id=CR50
citation_journal_title=J Nat Cancer Inst; citation_title=Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model; citation_author=DS Alberts, YM Peng, HS Chen; citation_volume=65; citation_publication_date=1980; citation_pages=455-461; citation_id=CR51
citation_journal_title=Brit J Cancer; citation_title=Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin; citation_author=G Los, MJ van Vugt, HM Pinedo; citation_volume=69; citation_publication_date=1994; citation_pages=235-241; citation_doi=10.1038/bjc.1994.45; citation_id=CR52
citation_journal_title=Int J Radiat Biol; citation_title=Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum(II); citation_author=M Akaboshi, Y Tanaka, K Kawai; citation_volume=66; citation_publication_date=1994; citation_pages=215-220; citation_doi=10.1080/09553009414551121; citation_id=CR53
citation_journal_title=Eur J Cancer; citation_title=Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines; citation_author=PJvan de Vaart, Nvan der Vange, FA Zoetmulder; citation_volume=34; citation_publication_date=1998; citation_pages=148-154; citation_doi=10.1016/S0959-8049(97)00370-5; citation_id=CR54
citation_journal_title=Semin Cancer Biol; citation_title=Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?; citation_author=P Borst, M Kool, R Evers; citation_volume=8; citation_publication_date=1997; citation_pages=205-213; citation_doi=10.1006/scbi.1997.0071; citation_id=CR55
citation_journal_title=Proc Natl Acad Sci USA; citation_title=High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis; citation_author=AK Godwin, A Meister, PJ O'Dwyer; citation_volume=89; citation_publication_date=1992; citation_pages=3070-3074; citation_doi=10.1073/pnas.89.7.3070; citation_id=CR56
citation_inbook_title=Augmantation of Adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine dediated glutathione depletion; citation_publication_date=1985; citation_pages=2583-2586; citation_id=CR57; citation_author=T Hamilton; citation_author=M Winker; citation_author=K Louie
citation_inbook_title=Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles; citation_publication_date=1987; citation_pages=1955-1964; citation_id=CR58; citation_author=P Dedon; citation_author=RE Borch
citation_journal_title=Biochem Pharmacol; citation_title=An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines; citation_author=LK Hosking, RD Whelan, SA Shellard; citation_volume=40; citation_publication_date=1990; citation_pages=1833-1842; citation_doi=10.1016/0006-2952(90)90364-Q; citation_id=CR59
citation_journal_title=Eur J Cancer; citation_title=Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo; citation_author=M Kojima, F Kikkawa, H Oguchi; citation_volume=30A; citation_publication_date=1994; citation_pages=773-778; citation_doi=10.1016/0959-8049(94)90291-7; citation_id=CR60
citation_inbook_title=Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines; citation_publication_date=1994; citation_pages=689-697; citation_id=CR61; citation_author=SW Johnson; citation_author=RP Perez; citation_author=AK Godwin
citation_inbook_title=Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells; citation_publication_date=1994; citation_pages=5911-5916; citation_id=CR62; citation_author=SW Johnson; citation_author=PA Swiggard; citation_author=LM Handel
citation_journal_title=Cancer Res; citation_title=Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II); citation_author=H Masuda, T Tanaka, H Matsuda; citation_volume=50; citation_publication_date=1990; citation_pages=1863-1866; citation_id=CR63
citation_inbook_title=The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells; citation_publication_date=1990; citation_pages=159-164; citation_id=CR64; citation_author=EJ Katz; citation_author=PA Andrews; citation_author=SB Howell
citation_journal_title=Carcinogenesis; citation_title=Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro; citation_author=WC Dempke, SA Shellard, AM Fichtinger-Schepman; citation_volume=12; citation_publication_date=1991; citation_pages=525-528; citation_doi=10.1093/carcin/12.3.525; citation_id=CR65
citation_inbook_title=Mechanisms of action of arsenic trioxide; citation_publication_date=2002; citation_pages=3893-3903; citation_id=CR66; citation_author=WH Miller; citation_author=HM Schipper; citation_author=JS Lee
citation_inbook_title=Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts; citation_publication_date=1997; citation_pages=399-405; citation_id=CR67; citation_author=A Hartwig; citation_author=UD Groblinghoff; citation_author=D Beyersmann
citation_inbook_title=Induction of gene amplification by arsenic; citation_publication_date=1988; citation_pages=79-81; citation_id=CR68; citation_author=TC Lee; citation_author=N Tanaka; citation_author=PW Lamb
citation_inbook_title=Stress proteins induced by arsenic; citation_publication_date=2001; citation_pages=132-148; citation_id=CR69; citation_author=LM Del Razo; citation_author=B Quintanilla-Vega; citation_author=E Brambila-Colombres
citation_inbook_title=Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required; citation_publication_date=2004; citation_pages=32700-32708; citation_id=CR70; citation_author=EM Leslie; citation_author=A Haimeur; citation_author=MP Waalkes
citation_inbook_title=Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals; citation_publication_date=2004; citation_pages=871-878; citation_id=CR71; citation_author=H Shi; citation_author=LG Hudson; citation_author=W Ding
citation_inbook_title=Oxidative stress and apoptosis in metal ion-induced carcinogenesis; citation_publication_date=2004; citation_pages=582-593; citation_id=CR72; citation_author=H Shi; citation_author=LG Hudson; citation_author=KJ Liu
citation_inbook_title=Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells; citation_publication_date=2005; citation_pages=4013-4020; citation_id=CR73; citation_author=AM Ramos; citation_author=C Fernandez; citation_author=D Amran
citation_inbook_title=Arsenic in cancer therapy; citation_publication_date=2005; citation_pages=119-127; citation_id=CR74; citation_author=J Hu; citation_author=J Fang; citation_author=Y Dong
citation_inbook_title=p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1; citation_publication_date=2006; citation_pages=142-151; citation_id=CR75; citation_author=BF Taylor; citation_author=SC McNeely; citation_author=HL Miller
citation_inbook_title=Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells; citation_publication_date=2005; citation_pages=877-887; citation_id=CR76; citation_author=G McCollum; citation_author=PC Keng; citation_author=JC States
citation_inbook_title=Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. [erratum appears in Toxicol Appl Pharmacol 2002 Sep 1, 183(2):152]; citation_publication_date=2002; citation_pages=83-91; citation_id=CR77; citation_author=JC States; citation_author=JJ Reiners; citation_author=JG Pounds
citation_inbook_title=Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase; citation_publication_date=2000; citation_pages=724-733; citation_id=CR78; citation_author=MJ McCabe; citation_author=KP Singh; citation_author=SA Reddy
citation_inbook_title=Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells; citation_publication_date=1994; citation_pages=5902-5910; citation_id=CR79; citation_author=SP Cole; citation_author=KE Sparks; citation_author=K Fraser
citation_inbook_title=History of the development of arsenic derivatives in cancer therapy; citation_publication_date=2001; citation_pages=3-10; citation_id=CR80; citation_author=S Waxman; citation_author=KC Anderson
citation_journal_title=J Pharmacol Exp Ther; citation_title=Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite; citation_author=J Liu, Y Lu, Q Wu; citation_volume=326; citation_publication_date=2008; citation_pages=363-368; citation_doi=10.1124/jpet.108.139543; citation_id=CR81
citation_inbook_title=Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene; citation_publication_date=2001; citation_pages=4-11; citation_id=CR82; citation_author=MH Cohen; citation_author=S Hirschfeld; citation_author=S Flamm Honig
citation_inbook_title=Clinical trials referral resource. Clinical trials with arsenic trioxide; citation_publication_date=2000; citation_pages=206; citation_id=CR83; citation_author=AJ Murgo; citation_author=WL McBee; citation_author=BD Cheson
citation_inbook_title=Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies; citation_publication_date=2001; citation_pages=22-28; citation_id=CR84; citation_author=AJ Murgo
citation_journal_title=Cancer Chemother Pharmacol; citation_title=Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines; citation_author=YH Du, PC Ho, YH Du; citation_volume=47; citation_publication_date=2001; citation_pages=481-490; citation_doi=10.1007/s002800100278; citation_id=CR85
citation_inbook_title=Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines; citation_publication_date=2000; citation_pages=4957-4964; citation_id=CR86; citation_author=R Uslu; citation_author=UA Sanli; citation_author=C Sezgin
citation_journal_title=Gynecol Oncol; citation_title=Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line; citation_author=J Bornstein, S Sagi, A Haj; citation_volume=99; citation_publication_date=2005; citation_pages=726-729; citation_doi=10.1016/j.ygyno.2005.07.125; citation_id=CR87
citation_journal_title=Int J Gynecol Cancer; citation_title=Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines; citation_author=B Kong, S Huang, W Wang; citation_volume=15; citation_publication_date=2005; citation_pages=872-877; citation_doi=10.1111/j.1525-1438.2005.00251.x; citation_id=CR88
citation_journal_title=Gynecol Oncol; citation_title=Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo; citation_author=J Zhang, B Wang; citation_volume=103; citation_publication_date=2006; citation_pages=199-206; citation_doi=10.1016/j.ygyno.2006.02.037; citation_id=CR89
citation_journal_title=Int J Cancer; citation_title=Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells; citation_author=M Baumgartner, S Sturlan, E Roth; citation_volume=112; citation_publication_date=2004; citation_pages=707-712; citation_doi=10.1002/ijc.20462; citation_id=CR90
citation_inbook_title=Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma; citation_publication_date=2001; citation_pages=702-705; citation_id=CR91; citation_author=W Wang; citation_author=SK Qin; citation_author=BA Chen